

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	CA/CAPLUS records now contain indexing from 1907 to the present
NEWS	4	Jul 15	Data from 1960-1976 added to RDISCLOSURE
NEWS	5	Jul 21	Identification of STN records implemented
NEWS	6	Jul 21	Polymer class term count added to REGISTRY
NEWS	7	Jul 22	INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available
NEWS	8	AUG 05	New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS	9	AUG 13	Field Availability (/FA) field enhanced in BEILSTEIN
NEWS	10	AUG 15	PATDPAFULL: one FREE connect hour, per account, in September 2003
NEWS	11	AUG 15	PCTGEN: one FREE connect hour, per account, in September 2003
NEWS	12	AUG 15	RDISCLOSURE: one FREE connect hour, per account, in September 2003
NEWS	13	AUG 15	TEMA: one FREE connect hour, per account, in September 2003
NEWS	14	AUG 18	Data available for download as a PDF in RDISCLOSURE
NEWS	15	AUG 18	Simultaneous left and right truncation added to PASCAL
NEWS	16	AUG 18	FROSTI and KOSMET enhanced with Simultaneous Left and Right Truncation
NEWS	17	AUG 18	Simultaneous left and right truncation added to ANABSTR
NEWS	18	SEP 22	DIPPR file reloaded
NEWS	19	SEP 25	INPADOC: Legal Status data to be reloaded
NEWS	20	SEP 29	DISSABS now available on STN
NEWS EXPRESS			April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 14:44:56 ON 30 SEP 2003

=> file medline, uspatful, dgene, wpids, fsta, biosis		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 14:45:19 ON 30 SEP 2003

FILE 'USPATFULL' ENTERED AT 14:45:19 ON 30 SEP 2003  
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 14:45:19 ON 30 SEP 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WPIDS' ENTERED AT 14:45:19 ON 30 SEP 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 14:45:19 ON 30 SEP 2003  
COPYRIGHT (C) 2003 International Food Information Service

FILE 'BIOSIS' ENTERED AT 14:45:19 ON 30 SEP 2003  
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

```
=> e shimkets,r/au
E1      4      SHIMKETS RICHARD AUGUST/AU
E2      2      SHIMKETS RICK/AU
E3      0  --> SHIMKETS,R/AU
E4      2      SHIMKEVICH A L/AU
E5      2      SHIMKEVICH A M/AU
E6      3      SHIMKEVICH ALEXANDER LVOVICH/AU
E7      2      SHIMKEVICH ANDREY M/AU
E8      12     SHIMKEVICH I A/AU
E9      2      SHIMKEVICH L D/AU
E10     86     SHIMKEVICH L L/AU
E11     6      SHIMKEVICH R L/AU
E12     1      SHIMKEVICH S V/AU
```

```
=> s e1
L1      4      "SHIMKETS RICHARD AUGUST"/AU
```

```
=> s e2
L2      2      "SHIMKETS RICK"/AU
```

```
=> d l1 ti abs ibib tot
```

```
L1  ANSWER 1 OF 4  USPATFULL on STN
TI  Atrial natriuretic factor mutants and ischemic stroke
AB  The present invention is based upon the observation that a mutant atrial
    natriuretic factor (ANF) gene increases stroke latency in spontaneously
    hypertensive rats-stroke prone (SHRSP). Accordingly, the present
    invention provides methods using mutant ANF proteins, fragments,
    analogs, derivatives and homologs of mutant ANF proteins, the nucleic
    acids encoding these mutant ANF proteins, as well as modulators of ANF
    for treating or preventing ischemic diseases, in particular ischemic
    stroke. The invention also relates to methods of diagnosis, prognosis
    and screening for a disposition for diseases and disorders associated
    with increased levels of ANF. Pharmaceutical compositions, methods of
    screening for ANF mutants and ANF modulators with utility for treatment
    and prevention of ischemic stroke are also provided.
```

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
ACCESSION NUMBER: 2003:33456 USPATFULL

TITLE: Atrial natriuretic factor mutants and ischemic stroke  
INVENTOR(S): **Shimkets, Richard August**, West Haven, CT,  
United States  
PATENT ASSIGNEE(S): CuraGen Corporation, New Haven, CT, United States (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6514939	B1	20030204
APPLICATION INFO.:	US 1999-428929		19991028 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-916043, filed on 21 Aug 1997, now patented, Pat. No. US 6013630		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Allen, Marianne P.		
LEGAL REPRESENTATIVE:	Mintz Levin, Biswas, Naomi S., Elrifi, Ivor R.		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 10 Drawing Page(s)		
LINE COUNT:	2353		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 2 OF 4 USPATFULL on STN  
TI Atrial natriuretic factor mutants and ischemic stroke  
AB The present invention is based upon the observation that a mutant atrial  
natriuretic factor (ANF) gene increases stroke latency in spontaneously  
hypertensive rats-stroke prone (SHRSP). Accordingly, the present  
invention provides methods using mutant ANF proteins, fragments,  
analogs, derivatives and homologs of mutant ANF proteins, the nucleic  
acids encoding these mutant ANF proteins, as well as modulators of ANF  
for treating or preventing ischemic diseases, in particular ischemic  
stroke. The invention also relates to methods of diagnosis, prognosis  
and screening for a disposition for diseases and disorders associated  
with increased levels of ANF. Pharmaceutical compositions, methods of  
screening for ANF mutants and ANF modulators with utility for treatment  
and prevention of ischemic stroke are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:4792 USPATFULL  
TITLE: Atrial natriuretic factor mutants and ischemic stroke  
INVENTOR(S): **Shimkets, Richard August**, West Haven, CT,  
United States  
PATENT ASSIGNEE(S): CuraGen Corporation, New Haven, CT, United States (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6013630		20000111
APPLICATION INFO.:	US 1997-916043		19970821 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Allen, Marianne P.		
LEGAL REPRESENTATIVE:	Elrifi, Ivor R. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo P.C., Johnson, David E.		
NUMBER OF CLAIMS:	28		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 10 Drawing Page(s)		
LINE COUNT:	2390		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 3 OF 4 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN  
TI Atrial natriuretic factor mutants and ischemic stroke.  
AB The present invention is based upon the observation that a mutant atrial  
natriuretic factor (ANF) gene increases stroke latency in spontaneously

hypertensive rats-stroke prone (SHRSP). Accordingly, the present invention provides methods using mutant ANF proteins, fragments, analogs, derivatives and homologs of mutant ANF proteins, the nucleic acids encoding these mutant ANF proteins, as well as modulators of ANF for treating or preventing ischemic diseases, in particular ischemic stroke. The invention also relates to methods of diagnosis, prognosis and screening for a disposition for diseases and disorders associated with increased levels of ANF. Pharmaceutical compositions, methods of screening for ANF mutants and ANF modulators with utility for treatment and prevention of ischemic stroke are also provided.

ACCESSION NUMBER: 2003:129778 BIOSIS  
DOCUMENT NUMBER: PREV200300129778  
TITLE: Atrial natriuretic factor mutants and ischemic stroke.  
AUTHOR(S): **Shimkets, Richard August**  
ASSIGNEE: CuraGen Corporation  
PATENT INFORMATION: US 6514939 February 04, 2003  
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Feb. 4 2003) Vol. 1267, No. 1, pp. No  
Pagination. <http://www.uspto.gov/web/menu/patdata.html>.  
e-file.  
ISSN: 0098-1133.  
DOCUMENT TYPE: Patent  
LANGUAGE: English

L1 ANSWER 4 OF 4 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN  
TI Atrial natriuretic factor mutants and ischemic stroke.  
AB The present invention is based upon the observation that a mutant atrial natriuretic factor (ANF) gene increases stroke latency in spontaneously hypertensive rats-stroke prone (SHRSP). Accordingly, the present invention provides methods using mutant ANF proteins, fragments, analogs, derivatives and homologs of mutant ANF proteins, the nucleic acids encoding these mutant ANF proteins, as well as modulators of ANF for treating or preventing ischemic diseases, in particular ischemic stroke. The invention also relates to methods of diagnosis, prognosis and screening for a disposition for diseases and disorders associated with increased levels of ANF. Pharmaceutical compositions, methods of screening for ANF mutants and ANF modulators with utility for treatment and prevention of ischemic stroke are also provided.

ACCESSION NUMBER: 2000:319969 BIOSIS  
DOCUMENT NUMBER: PREV200000319969  
TITLE: Atrial natriuretic factor mutants and ischemic stroke.  
AUTHOR(S): **Shimkets, Richard August (1)**  
CORPORATE SOURCE: (1) West Haven, CT USA  
ASSIGNEE: CuraGen Corporation, New Haven, CT, USA  
PATENT INFORMATION: US 6013630 January 11, 2000  
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Jan. 11, 2000) Vol. 1230, No. 2, pp. No  
pagination. e-file.  
ISSN: 0098-1133.  
DOCUMENT TYPE: Patent  
LANGUAGE: English

=> d 12 ti abs ibib tot

L2 ANSWER 1 OF 2 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN  
TI Novel G-protein-coupled receptors: Structure and tissue expression analysis.  
AB The G-protein-coupled receptors (GPCRs) are cell surface molecules that transmit extracellular signals to intracellular messengers. The GPCR gene family is the largest known receptor family including an estimated 700-1000 odorant GPCRs. The ligands that bind GPCRs are small and can be easily mimicked by use of synthetic analogues making GPCRs ideal targets for the development of therapeutic agents. We have identified several

hundred GPCR-like genes in our effort to characterize novel drug targets. These genes undergo a systematic analysis. The genes are first cloned and then tissue expression profiles generated for both normal and disease conditions. Extensive in silico analysis of these genes is conducted at both the nucleotide and amino acid level to determine the homology and secondary structure. The tissue expression profiles are correlated with the DNA sequence for each gene to enable us to distinguish the non-expressed pseudogenes. Additional analysis is directed towards the study of the upstream DNA sequence from multiple GPCRs with similar tissue-expression profiles. This sequence is then evaluated for conserved residues/motifs/domains which may be associated with potential regulatory and promoter regions that define tissue-specific expression profiles. Results from these analyses will be presented.

ACCESSION NUMBER: 2001:514720 BIOSIS  
DOCUMENT NUMBER: PREV200100514720  
TITLE: Novel G-protein-coupled receptors: Structure and tissue expression analysis.  
AUTHOR(S): Padigaru, Muralidhara (1); Taupier, Ray (1); Zerhusen, Bryan (1); Herrmann, John (1); Burgess, Catherine (1); Braverman, Mike (1); Leach, Martin (1); Shenoy, Suresh (1); **Shimkets, Rick (1)**  
CORPORATE SOURCE: (1) CuraGen Corporation, Branford, CT USA  
SOURCE: International Genome Sequencing and Analysis Conference, (2000) Vol. 12, pp. 82. print.  
Meeting Info.: 12th International Genome Sequencing and Analysis Conference Miami Beach, Florida, USA September 12-15, 2000  
DOCUMENT TYPE: Conference  
LANGUAGE: English  
SUMMARY LANGUAGE: English

L2 ANSWER 2 OF 2 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STM  
TI Prioritization of targets by in silico profile generation.  
AB Genes differentially expressed between normal and diseased states offer an attractive target for drug-based intervention. CuraGen's proprietary gene expression technologies (SeqCalling, GeneCalling, Pharmacogenomics) employ a sophisticated bioinformatics platform that leads to the rapid identification of potential human disease targets and toxicology markers. The GeneCalling and Pharmacogenomics processes compare the gene expression of defined animal, tissue or cellular models of disease or drug-response to appropriate controls. For both of these methods, identification of differentially expressed genes does not require prior knowledge of gene sequence, a direct contrast to conventional chip-based technologies. Downstream sequence analysis of these potential targets is supplemented by cutting-edge genomics technologies and our proprietary human sequence database consisting of more than 4 million sequences. Target selection is further refined through the integration of the target's gene expression profile with our extensive protein:protein interaction database and high-throughput tissue distribution characterization. A completed profile of the selected target can therefore be rapidly and inversely engineered from the gene expression data. This dramatically reduces the non-productive consumption of resources while increasing the efficiency of selection. Further validation by wet-lab analysis is thereby directed toward targets that have the highest potential for downstream drug development or therapeutic intervention.

ACCESSION NUMBER: 2001:494515 BIOSIS  
DOCUMENT NUMBER: PREV200100494515  
TITLE: Prioritization of targets by in silico profile generation.  
AUTHOR(S): Burgess, Catherine (1); Braverman, Mike (1); Leach, Martin (1); Gould-Rothberg, Bonnie (1); **Shimkets, Rick (1)**  
CORPORATE SOURCE: (1) CuraGen Corporation, Branford, CT USA  
SOURCE: International Genome Sequencing and Analysis Conference, (2000) Vol. 12, pp. 52. print.  
Meeting Info.: 12th International Genome Sequencing and

Analysis Conference Miami Beach, Florida, USA September  
12-15, 2000  
DOCUMENT TYPE: Conference  
LANGUAGE: English  
SUMMARY LANGUAGE: English

=> d his

(FILE 'HOME' ENTERED AT 14:44:56 ON 30 SEP 2003)

FILE 'MEDLINE, USPATFULL, DGENE, WPIDS, FSTA, BIOSIS' ENTERED AT 14:45:19  
ON 30 SEP 2003

E SHIMKETS,R/AU  
L1 4 S E1  
L2 2 S E2

=> e fernandes, e/au

E1 1 FERNANDES Z Z/AU  
E2 5 FERNANDES ZSCHABER R M/AU  
E3 0 --> FERNANDES, E/AU  
E4 10 FERNANDESALNEMRI T/AU  
E5 1 FERNANDESHJDE B/AU  
E6 1 FERNANDESM J M/AU  
E7 1 FERNANDEX A/AU  
E8 1 FERNANDEX C/AU  
E9 1 FERNANDEX DE LA VEGA CARLOS SANCHEZ/AU  
E10 1 FERNANDEX DEL PALACIO M J/AU  
E11 1 FERNANDEX E GARCIA/AU  
E12 1 FERNANDEX FERNANDEZ M/AU

=> s PROX polypeptide

L3 2 PROX POLYPEPTIDE

=> d l3 ti abs ibib tot

L3 ANSWER 1 OF 2 USPATFULL on STN  
TI Novel amino acid sequences for human fetal brain-like polypeptides  
AB This application is drawn to novel amino acid sequences for mammalian  
polypeptides that have sequence similarity to fetal brain tissue  
protein. The polypeptides are novel secreted proteins 649 amino acids in  
length.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:4266 USPATFULL  
TITLE: Novel amino acid sequences for human fetal brain-like  
polypeptides  
INVENTOR(S): Shimkets, Richard A., West Haven, CT, UNITED STATES  
Fernandes, Elma, Branford, CT, UNITED STATES  
PATENT ASSIGNEE(S): CuraGen Corporation, New Haven, CT (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003004310	A1	20030102
APPLICATION INFO.:	US 2001-4551	A1	20011205 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-635949, filed on 10 Aug 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-148433P	19990811 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MINTZ, LEVIN, COHN, FERRIS,, GLOVSKY AND POPEO, P.C.,	

One Financial Center, Boston, MA, 02111  
NUMBER OF CLAIMS: 15  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 5 Drawing Page(s)  
LINE COUNT: 6347  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 2 OF 2 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN  
TI Nucleic acids encoding secreted polypeptides, designated PROX  
polypeptides, useful for treating a syndrome associated with a  
PROX-associated disorder, e.g. cancer.  
AN 2001-147509 [15] WPIDS  
AB WO 200110902 A UPAB: 20011129  
NOVELTY - Isolated nucleic acids encoding secreted polypeptides,  
designated PROX polypeptides (i.e. a PRO polypeptide where X is an integer  
from 1 to 17), are new.

DETAILED DESCRIPTION - Isolated nucleic acids encoding secreted  
polypeptides, designated PROX polypeptides (i.e. a PRO polypeptide where X  
is an integer from 1 to 17), are new.

A nucleic acid (N1) encoding a **PROX polypeptide**  
is selected from:

- (a) a nucleic acid encoding a mature form of a polypeptide selected  
from one of the 17 amino acid sequences (P1) defined in the specification;
- (b) a nucleic acid encoding a variant of a mature form of a sequence  
selected from P1, where one or more amino acid residues differ from the  
sequence of the mature form, provided that the variant differs in no more  
than 15% of the residues from the sequence of the mature form;
- (c) a nucleic acid encoding an amino acid sequence selected from P1;
- (d) a nucleic acid encoding a variant of a sequence selected from P1,  
where one or more amino acid residues differ from the sequence of the  
mature form, provided that the variant differs in no more than 15% of the  
residues from the amino acid sequence selected from P1;
- (e) a nucleic acid fragment encoding at least a portion of an amino  
acid sequence selected from P1, or a variant of the polypeptide, where one  
or more residues in the variant differs from the sequence of the mature  
form, provided that the variant differs in no more than 15% of the  
residues from the amino acid sequence selected from P1; or
- (f) a nucleic acid comprising the complement of (a)-(e).

INDEPENDENT CLAIMS are also included for the following:

- (1) an isolated polypeptide (P2) comprising an amino acid sequence  
selected from:
  - (a) a mature form of a polypeptide selected from P1;
  - (b) a variant of a mature form of a sequence selected from P1, where  
one or more amino acid residues differ from the sequence of the mature  
form, provided that the variant differs in no more than 15% of the  
residues from the sequence of the mature form;
  - (c) an amino acid sequence selected from P1;
  - (d) a variant of a sequence selected from P1, where one or more amino  
acid residues differ from the sequence of the mature form, provided that  
the variant differs in no more than 15% of the residues from the amino  
acid sequence selected from P1;
- (2) a vector comprising N1 operably linked to a promoter;
- (3) a cell comprising the vector of (2);
- (4) an antibody (Ab1) that immunospecifically binds to P2;
- (5) a method of determining the presence or amount of P2 in a sample,  
comprising:
  - (a) contacting the sample with Ab1; and
  - (b) determining the presence or amount of Ab1 bound to the  
polypeptide, therefore determining the presence or amount of P2 in the  
sample;
- (6) a method of determining the presence or amount of N1 in a sample,  
comprising:
  - (a) contacting the sample with a probe that binds to N1; and
  - (b) determining the presence or amount of the probe bound to the

nucleic acid;

(7) a method of identifying an agent that binds to P2, comprising contacting the polypeptide with the agent and determining whether the agent binds to the polypeptide;

(8) a method of identifying an agent that modulates the expression or activity of P2, comprising:

(a) providing a cell expressing the polypeptide;

(b) contacting the cell with the agent; and

(c) determining whether the agent modulates expression or activity of the polypeptide, where an alteration in expression or activity of the polypeptide indicates that the agent modulates expression or activity of the polypeptide;

(9) a method for modulating the activity of P2, comprising contacting a cell sample expressing P2 with a compound that binds to the polypeptide in an amount sufficient to modulate the activity of the polypeptide;

(10) a method of treating or preventing a PROX-associated disorder in a human, comprising administering P2, N1 or Ab1;

(11) a kit comprising P2, N1 or Ab1;

(12) a method (M1) for screening for a modulator of activity or of latency or predisposition to a PROX-associated disorder, comprising:

(a) administering a test compound to a test animal at increased risk for a PROX-associated disorder, where the test animal recombinantly expresses P2;

(b) measuring the activity of the polypeptide in the test animal after administering the test compound; and

(c) comparing the activity of the protein in the test animal with the activity of the polypeptide in a control animal not administered the compound, where a change in the activity of the polypeptide in the test animal relative to the control animal indicates the test compound is a modulator of latency or predisposition to a PROX-associated disorder;

(13) a method for determining the presence of or predisposition to a disease associated with altered levels of P2 in a first mammalian subject, comprising:

(a) measuring the level of expression of the polypeptide in a sample from the first mammalian subject; and

(b) comparing the amount of the polypeptide in the sample of step (a) to the amount of polypeptide present in a control sample from a second mammalian subject known not to have, or not to be predisposed to the disease, where an alteration in the expression level of the polypeptide in the first subject as compared to the control sample indicates the presence of or predisposition to the disease;

(14) a method for determining the presence of or predisposition to a disease associated with altered levels of N1 in a first mammalian subject;

(15) a method of treating a pathological state in a mammal, comprising administering a polypeptide in an amount that is sufficient to alleviate the pathological state, where the polypeptide has a sequence at least 95% identical to a polypeptide comprising an amino acid sequence selected from P1, or its biologically active fragment; and

(16) a method of treating a pathological state in a mammal, comprising administering Ab1 in an amount that is sufficient to alleviate the pathological state.

ACTIVITY - Cytostatic; Immunomodulatory; reproduction general.

No biological data given.

MECHANISM OF ACTION - Gene therapy; PROX antagonist; PROX agonist.

USE - The PROX polypeptide, nucleic acid and antibody are useful in the manufacture of a medicament for treating a syndrome associated with a PROX-associated disorder (claimed), e.g. a cell proliferation and/or differentiation disorder (e.g. cancer or immune associated disorders) and a gestational disease (e.g. pre-eclampsia).

They are also used for screening for a modulator of activity or of latency or predisposition to a PROX-associated disorder.

Dwg.0/9

ACCESSION NUMBER: 2001-147509 [15] WPIDS  
DOC. NO. CPI: C2001-043750



TITLE: Nucleic acids encoding secreted polypeptides, designated PROX polypeptides, useful for treating a syndrome associated with a PROX-associated disorder, e.g. cancer.

DERWENT CLASS: B04 D16

INVENTOR(S): FERNANDES, E; SHIMKETS, R A

PATENT ASSIGNEE(S): (CURA-N) CURAGEN CORP

COUNTRY COUNT: 95

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001010902	A2	20010215	(200115)*	EN	166
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
AU 2000068997	A	20010305	(200130)		
EP 1218406	A1	20020703	(200251)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI					
US 2003004310	A1	20030102	(200305)		
JP 2003508030	W	20030304	(200319)		236

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001010902	A2	WO 2000-US21857	20000811
AU 2000068997	A	AU 2000-68997	20000811
EP 1218406	A1	EP 2000-957365	20000811
		WO 2000-US21857	20000811
US 2003004310	A1	US 1999-148433P	19990811
	Provisional	US 2000-635949	20000810
	Cont of	US 2001-4551	20011205
JP 2003508030	W	WO 2000-US21857	20000811
		JP 2001-515709	20000811

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2000068997	A	WO 2001010902
EP 1218406	A1	WO 2001010902
JP 2003508030	W	WO 2001010902

PRIORITY APPLN. INFO: US 2000-635949 20000810; US 1999-148433P 19990811; US 2001-4551 20011205

**WEST**[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Terms	Documents
l5 and L7	0

**Database:**

[US Patents Full-Text Database](#)  
[US Pre-Grant Publication Full-Text Database](#)  
[JPO Abstracts Database](#)  
[EPO Abstracts Database](#)  
[Derwent World Patents Index](#)  
[IBM Technical Disclosure Bulletins](#)

**Search:**

L8

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History**
**DATE: Tuesday, September 30, 2003**
[Printable Copy](#)
[Create Case](#)
**Set Name Query**  
 side by side

**Hit Count Set Name**  
 result set
*DB=USPT; PLUR=YES; OP=OR*

<u>L8</u>	l5 and L7	0	<u>L8</u>
<u>L7</u>	l1 and L6	15	<u>L7</u>
<u>L6</u>	fernandes.in.	193	<u>L6</u>
<u>L5</u>	l1 and L4	5	<u>L5</u>
<u>L4</u>	Shimkets.in.	6	<u>L4</u>
<u>L3</u>	protease inhibitor and L2	36064	<u>L3</u>
<u>L2</u>	L1 and cancer	17499	<u>L2</u>
<u>L1</u>	PROX polypeptide	43127	<u>L1</u>

END OF SEARCH HISTORY

**WEST**

Generate Collection

Print

**Search Results - Record(s) 1 through 10 of 15 returned.**☐ 1. Document ID: US 6566505 B2

L7: Entry 1 of 15

File: USPT

May 20, 2003

US-PAT-NO: 6566505

DOCUMENT-IDENTIFIER: US 6566505 B2

TITLE: Antibodies to Mch6 polypeptides

DATE-ISSUED: May 20, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alnemri; Emad S.	Ambler	PA		
<u>Fernandes-Alnemri; Teresa</u>	Ambler	PA		
Litwack; Gerald	Bryn Mawr	PA		

US-CL-CURRENT: 530/387.9; 530/388.26, 530/389.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-------

☐ 2. Document ID: US 6462175 B1

L7: Entry 2 of 15

File: USPT

Oct 8, 2002

US-PAT-NO: 6462175

DOCUMENT-IDENTIFIER: US 6462175 B1

TITLE: Mch3, a novel apoptotic protease, nucleic acids encoding and methods of use

DATE-ISSUED: October 8, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alnemri; Emad S.	Ambler	PA		
<u>Fernandes-Alnemri; Teresa</u>	Ambler	PA		
Litwack; Gerald	Wynnewood	PA		
Armstrong; Robert	San Diego	CA		
Tomaselli; Kevin	La Jolla	CA		

US-CL-CURRENT: 530/350; 435/226, 530/300

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-------

☐ 3. Document ID: US 6455296 B2

L7: Entry 3 of 15

File: USPT

Sep 24, 2002

US-PAT-NO: 6455296

DOCUMENT-IDENTIFIER: US 6455296 B2

TITLE: Apoptotic protease Mch6, nucleic acids encoding same and methods of use

DATE-ISSUED: September 24, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alnemri; Emad S.	Ambler	PA		
Fernandes-Alnemri; Teresa	Ambler	PA		
Litwack; Gerald	Wynnewood	PA		

US-CL-CURRENT: 435/226; 435/219

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-------

☐ 4. Document ID: US 6287795 B1

L7: Entry 4 of 15

File: USPT

Sep 11, 2001

US-PAT-NO: 6287795

DOCUMENT-IDENTIFIER: US 6287795 B1

TITLE: Mch4 and Mch5, apoptotic protease, nucleic acids encoding and methods of use

DATE-ISSUED: September 11, 2001

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alnemri; Emad S.	Ambler	PA		
Fernandes-Alnemri; Teresa	Ambler	PA		
Litwack; Gerald	Wynnewood	PA		
Armstrong; Robert	San Diego	CA		
Tomaselli; Kevin	La Jolla	CA		

US-CL-CURRENT: 435/23; 435/219, 435/325, 435/7.21, 435/7.72, 435/7.91, 536/23.2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	------	-----------	-------

☐ 5. Document ID: US 6274318 B1

L7: Entry 5 of 15

File: USPT

Aug 14, 2001

US-PAT-NO: 6274318

DOCUMENT-IDENTIFIER: US 6274318 B1

**\*\* See image for Certificate of Correction \*\***

TITLE: Apoptotic protease Mch6, nucleic acids encoding same and methods of us

DATE-ISSUED: August 14, 2001

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alnemri; Emad S.	Ambler	PA		
<u>Fernandes-Alnemri; Teresa</u>	Ambler	PA		
Litwack; Gerald	Wynnewood	PA		

US-CL-CURRENT: 435/6; 435/226, 435/23, 435/7.6, 435/7.71, 435/7.72, 435/7.9

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw. Desc	Image
------	------------	-------

☐ 6. Document ID: US 6271361 B1

L7: Entry 6 of 15

File: USPT

Aug 7, 2001

US-PAT-NO: 6271361

DOCUMENT-IDENTIFIER: US 6271361 B1

TITLE: Apoptotic protease Mch6, nucleic acids encoding same and methods of use

DATE-ISSUED: August 7, 2001

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alnemri; Emad S.	Ambler	PA		
<u>Fernandes-Alnemri; Teresa</u>	Ambler	PA		
Litwack; Gerald	Wynnewood	PA		

US-CL-CURRENT: 536/23.2; 435/226, 435/320.1, 435/69.1, 536/23.5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw. Desc	Image
------	------------	-------

☐ 7. Document ID: US 5861498 A

L7: Entry 7 of 15

File: USPT

Jan 19, 1999

US-PAT-NO: 5861498

DOCUMENT-IDENTIFIER: US 5861498 A

**\*\* See image for Certificate of Correction \*\***

TITLE: Nucleotides encoding immunophilin FKBP46 and fragments thereof

DATE-ISSUED: January 19, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alnemri; Emad S.	Ambler	PA		
<u>Fernandes-Alnemri; Teresa</u>	Ambler	PA		
Litwack; Gerald	Wynnewood	PA		

US-CL-CURRENT: 536/23.5; 435/320.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw. Desc	Image
------	------------	-------

☐ 8. Document ID: US 5858778 A

L7: Entry 8 of 15

File: USPT

Jan 12, 1999

US-PAT-NO: 5858778

DOCUMENT-IDENTIFIER: US 5858778 A

TITLE: SF caspase-1 and compositions for making and methods of using the same

DATE-ISSUED: January 12, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alnemri; Emad S.	Ambler	PA		
Fernandes-Alnemri; Teresa	Ambler	PA		
Litwack; Gerald	Bryn Mawr	PA		

US-CL-CURRENT: 435/325; 435/219, 435/252.3, 435/252.33, 435/254.11, 435/320.1,  
435/348, 536/23.2, 536/24.3, 536/24.31

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KMC	Draw Desc	Image
-----	-----------	-------

☐ 9. Document ID: US 5851815 A

L7: Entry 9 of 15

File: USPT

Dec 22, 1998

US-PAT-NO: 5851815

DOCUMENT-IDENTIFIER: US 5851815 A

TITLE: MCH4 and MCH5, apoptotic proteases

DATE-ISSUED: December 22, 1998

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alnemri; Emad S.	Ambler	PA		
Fernandes-Alnemri; Teresa	Ambler	PA		
Litwack; Gerald	Wynnewood	PA		
Armstrong; Robert	San Diego	CA		
Tomaselli; Kevin	La Jolla	CA		

US-CL-CURRENT: 435/219; 435/183, 435/212, 530/324

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KMC	Draw Desc	Image
-----	-----------	-------

☐ 10. Document ID: US 5786173 A

L7: Entry 10 of 15

File: USPT

Jul 28, 1998

US-PAT-NO: 5786173

DOCUMENT-IDENTIFIER: US 5786173 A

TITLE: MCH4 and MCH5, apoptotic protease, nucleic acids encoding and methods of use

DATE-ISSUED: July 28, 1998

INVENTOR - INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alnemri; Emad S.	Ambler	PA		
Fernandes-Alnemri; Teresa	Ambler	PA		
Litwack; Gerald	Wynnewood	PA		
Armstrong; Robert	San Diego	CA		
Tomaselli; Kevin	La Jolla	CA		

US-CL-CURRENT: [435/69.1](#); [435/183](#), [435/219](#), [435/252.3](#), [435/320.1](#), [435/70.1](#), [530/324](#), [530/350](#), [536/23.1](#), [536/23.5](#), [536/24.31](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

Generate Collection

Print

Terms	Documents
11 and L6	15

Display Format:

CIT

Change Format

[Previous Page](#)      [Next Page](#)

**WEST**[Generate Collection](#)[Print](#)**Search Results - Record(s) 11 through 15 of 15 returned.**☐ 11. Document ID: US 5702699 A

L7: Entry 11 of 15

File: USPT

Dec 30, 1997

US-PAT-NO: 5702699

DOCUMENT-IDENTIFIER: US 5702699 A

TITLE: Process for the recovery of lipophilic proteins

DATE-ISSUED: December 30, 1997

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hanisch; Wolfgang H.	Oakland	CA		
Fernandes; Peter	Walnut Creek	CA		

US-CL-CURRENT: 424/85.6; 530/351[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KWC](#) [Draw Desc](#) [Image](#)☐ 12. Document ID: US 5643566 A

L7: Entry 12 of 15

File: USPT

Jul 1, 1997

US-PAT-NO: 5643566

DOCUMENT-IDENTIFIER: US 5643566 A

TITLE: Formulation processes for lipophilic proteins

DATE-ISSUED: July 1, 1997

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hanisch; Wolfgang H.	Balmoral Heights			AU
Fernandes; Pete M.	Walnut Creek	CA		
Taforo; Terrance	Oakland	CA		
Thomson; James W.	Albany	CA		

US-CL-CURRENT: 424/85.4; 424/85.2, 424/85.6, 530/351[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KWC](#) [Draw Desc](#) [Image](#)☐ 13. Document ID: US 4992271 A

L7: Entry 13 of 15

File: USPT

Feb 12, 1991

US-PAT-NO: 4992271



DOCUMENT-IDENTIFIER: US 4992271 A

TITLE: Formulation for lipophilic IL-2 proteins

DATE-ISSUED: February 12, 1991

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hanisch; Wolfgang H.	Oakland	CA		
<u>Fernandes</u> ; Peter M.	Walnut Creek	CA		
Taforo; Terrance	Oakland	CA		

US-CL-CURRENT: 424/85.2; 424/85.1, 424/85.4, 424/85.5, 424/85.6, 424/85.7, 435/811,  
514/12, 514/2, 514/21, 514/8, 514/885, 514/970, 530/351

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KMC	Draw Desc	Image
-----	-----------	-------

☐ 14. Document ID: US 4569910 A

L7: Entry 14 of 15

File: USPT

Feb 11, 1986

US-PAT-NO: 4569910

DOCUMENT-IDENTIFIER: US 4569910 A

TITLE: Methods and reagents for pyranosone production

DATE-ISSUED: February 11, 1986

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kohts; Kirston E.	Berkeley	CA		
Halenbeck; Robert F.	San Rafael	CA		
<u>Fernandes</u> ; Peter M.	Walnut Creek	CA		

US-CL-CURRENT: 435/105; 435/190, 435/911

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KMC	Draw Desc	Image
-----	-----------	-------

☐ 15. Document ID: US 4462940 A

L7: Entry 15 of 15

File: USPT

Jul 31, 1984

US-PAT-NO: 4462940

DOCUMENT-IDENTIFIER: US 4462940 A

TITLE: Process for the recovery of human .beta.-interferon-like polypeptides

DATE-ISSUED: July 31, 1984

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hanisch; Wolfgang H.	Oakland	CA		
<u>Fernandes</u> ; Peter M.	Lafayette	CA		

US-CL-CURRENT: 530/351; 424/85.6, 435/69.51, 435/811, 530/417, 530/424, 530/808,

530/825

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

Generate Collection

Print

Terms	Documents
11 and L6	15

Display Format:

CIT

Change Format

[Previous Page](#)      [Next Page](#)

**WEST**[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 5 of 5 returned.**☐ 1. Document ID: US 6610480 B1

L5: Entry 1 of 5

File: USPT

Aug 26, 2003

US-PAT-NO: 6610480

DOCUMENT-IDENTIFIER: US 6610480 B1

TITLE: Treatment and diagnosis of cardiac hypertrophy

DATE-ISSUED: August 26, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shimkets; Richard A.	West Haven	CT		
Lowe; David G.	Hillsborough	CA		

US-CL-CURRENT: [435/6](#); [536/23.1](#), [536/24.3](#), [536/24.31](#), [536/25.3](#)

<a href="#">Full</a>	<a href="#">Title</a>	<a href="#">Citation</a>	<a href="#">Front</a>	<a href="#">Review</a>	<a href="#">Classification</a>	<a href="#">Date</a>	<a href="#">Reference</a>	<a href="#">Sequences</a>	<a href="#">Attachments</a>	<a href="#">Claims</a>	<a href="#">KMC</a>	<a href="#">Draw Desc</a>	<a href="#">Image</a>
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	------------------------	---------------------	---------------------------	-----------------------

☐ 2. Document ID: US 6537554 B1

L5: Entry 2 of 5

File: USPT

Mar 25, 2003

US-PAT-NO: 6537554

DOCUMENT-IDENTIFIER: US 6537554 B1

TITLE: Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis

DATE-ISSUED: March 25, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shimkets; Richard A.	West Haven	CT		
Jeffers; Michael	Branford	CT		

US-CL-CURRENT: [424/198.1](#); [424/184.1](#), [435/4](#), [436/64](#)

<a href="#">Full</a>	<a href="#">Title</a>	<a href="#">Citation</a>	<a href="#">Front</a>	<a href="#">Review</a>	<a href="#">Classification</a>	<a href="#">Date</a>	<a href="#">Reference</a>	<a href="#">Sequences</a>	<a href="#">Attachments</a>	<a href="#">Claims</a>	<a href="#">KMC</a>	<a href="#">Draw Desc</a>	<a href="#">Image</a>
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	------------------------	---------------------	---------------------------	-----------------------

☐ 3. Document ID: US 6514939 B1

L5: Entry 3 of 5

File: USPT

Feb 4, 2003

US-PAT-NO: 6514939

DOCUMENT-IDENTIFIER: US 6514939 B1

TITLE: Atrial natriuretic factor mutants and ischemic stroke

DATE-ISSUED: February 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
<u>Shimkets</u> ; Richard August	West Haven	CT		

US-CL-CURRENT: 514/12; 530/324, 530/350

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-------

☐ 4. Document ID: US 6486299 B1

L5: Entry 4 of 5

File: USPT

Nov 26, 2002

US-PAT-NO: 6486299

DOCUMENT-IDENTIFIER: US 6486299 B1

TITLE: Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity

DATE-ISSUED: November 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
<u>Shimkets</u> ; Richard A.	West Haven	CT		

US-CL-CURRENT: 530/350; 530/380, 530/800

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------	-------

☐ 5. Document ID: US 6013630 A

L5: Entry 5 of 5

File: USPT

Jan 11, 2000

US-PAT-NO: 6013630

DOCUMENT-IDENTIFIER: US 6013630 A

TITLE: Atrial natriuretic factor mutants and ischemic stroke

DATE-ISSUED: January 11, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
<u>Shimkets</u> ; Richard August	West Haven	CT		

US-CL-CURRENT: 514/12; 530/324

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

Generate Collection

Print

Terms	Documents
11 and L4	5

---

**Display Format:**

CIT

Change Format

[Previous Page](#)[Next Page](#)